[HTML][HTML] Potent graft-versus-leukemia effect after reduced intensity (RIC) allogeneic stem-cell transplantation (asct) as post-remission therapy for intermediate-risk de …
G Labouré, S Dulucq, S Vigouroux, E Lippert… - Blood, 2011 - Elsevier
Abstract 4129 In patients with cytogenetically normal AML, the mutational status of FLT3,
NPM1 and CEBPA are associated with the outcome (Schlenk, NEJM 2008). In that study, the …
NPM1 and CEBPA are associated with the outcome (Schlenk, NEJM 2008). In that study, the …
[HTML][HTML] Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - Elsevier
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
[HTML][HTML] Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD
AD Ho, J Schetelig, T Bochtler, M Schaich… - Biology of Blood and …, 2016 - Elsevier
Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in
patients with FLT3-ITD–positive intermediate-risk acute myeloid leukemia (AML) remains …
patients with FLT3-ITD–positive intermediate-risk acute myeloid leukemia (AML) remains …
[HTML][HTML] Allogeneic stem cell transplantation improves survival in patients with FLT3-ITD-negative and NPM1-wild type intermediate risk (ELN) acute myeloid leukemia
K Heidrich, C Thiede, K Schäfer-Eckart, N Schmitz… - Blood, 2016 - Elsevier
Background: So called triple-negative acute myeloid leukemias (AML) form a
heterogeneous subgroup of intermediate-risk AML according to ELN criteria. Molecularly …
heterogeneous subgroup of intermediate-risk AML according to ELN criteria. Molecularly …
[HTML][HTML] Allogeneic hematopoietic stem-cell transplantation (HSCT) in first complete remission is superior compared to chemotherapy/autologous HSCT in patients …
Prognosis of acute myeloid leukemia (AML) is mainly determined by presenting cyto-and
molecular genetics, as systematized in the recent European LeukemiaNet (ELN) risk …
molecular genetics, as systematized in the recent European LeukemiaNet (ELN) risk …
[HTML][HTML] Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience
O Beyar-Katz, I Henig, D Yehudai, N Yuval, R Fineman… - Blood, 2016 - Elsevier
Introduction: Post-remission therapy in acute myeloid leukemia (AML) is mainly guided by
cytogenetic and molecular risks, patient age and performance status. Favorable AML is …
cytogenetic and molecular risks, patient age and performance status. Favorable AML is …
[HTML][HTML] FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis …
Background: While intensive consolidation therapy with autologous stem cell transplantation
(ASCT) can secure a remission in selected Acute Myeloid Leukemia (AML) patients with …
(ASCT) can secure a remission in selected Acute Myeloid Leukemia (AML) patients with …
Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML
L Wan, S Ding, M Xu, K Lv, Y Du, D Wu, M Xu… - International Journal of …, 2022 - Springer
Risks associated with the FLT3-ITD mutation in patients receiving chemotherapy alone for
cytogenetic normal acute myeloid leukemia (CN-AML) depend on the allelic ratio (AR) and …
cytogenetic normal acute myeloid leukemia (CN-AML) depend on the allelic ratio (AR) and …
[HTML][HTML] Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD, NPM1-or biallelicCEBPA mutations
K Heidrich, C Thiede, K Schäfer-Eckart, N Schmitz… - Annals of …, 2017 - Elsevier
Background The value of allogeneic hematopoietic cell transplantation (alloHCT) as
postremission treatment is not well defined for patients with intermediate-risk acute myeloid …
postremission treatment is not well defined for patients with intermediate-risk acute myeloid …
Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
P Niparuck, N Limsuwanachot, S Pukiat… - … Hematology & Oncology, 2019 - Springer
Background Cytogenetic abnormalities and mutated genes indicate the role of consolidation
therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute …
therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute …